| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| Gesamt | 2.056.733.459 $ | +473.627.665 $ | +202,9 % | 31 | 2.356.318.840 $ | +314.880.802 $ | +7,1 % | 29 | 2.204.008.593 $ | +638.709.769 $ | +61,2 % | 28 | |||
| Zymeworks Inc. | ZYME | → 0 | Schwach | 600.445.942 $ | +25.267.426 $ | +4,4 % | 1 | 575.178.516 $ | -29.631.800 $ | -4,9 % | 1 | 604.810.316 $ | +212.476.089 $ | +54,2 % | 1 |
| ANAPTYSBIO, INC | ANAB | → 0 | Neutral | 531.906.345 $ | +94.876.332 $ | +21,7 % | 1 | 437.030.013 $ | +55.003.056 $ | +14,4 % | 1 | 382.026.957 $ | +140.738.479 $ | +58,3 % | 1 |
| Jazz Pharmaceuticals plc | JAZZ | → 0 | Neutral | 322.607.964 $ | +32.508.234 $ | +11,2 % | 1 | 290.099.730 $ | +65.187.116 $ | +29,0 % | 1 | ||||
| Centessa Pharmaceuticals plc | CNTA | → 0 | 254.636.976 $ | +176.730.826 $ | +226,9 % | 1 | 77.906.150 $ | +64.568.650 $ | +484,1 % | 1 | |||||
| Crinetics Pharmaceuticals, Inc. | CRNX | → 0 | 155.744.518 $ | -43.867.468 $ | -22,0 % | 1 | 199.611.986 $ | +21.011.788 $ | +11,8 % | 1 | |||||
| Aktis Oncology, Inc. | AKTS | → 0 | 155.492.636 $ | +69.182.886 $ | +80,2 % | 1 | 86.309.750 $ | +86.309.750 $ | 1 | ||||||
| CG Oncology, Inc. | CGON | → 0 | Schwach | 146.064.590 $ | +71.481.230 $ | +95,8 % | 1 | 74.583.360 $ | +30.372.864 $ | +68,7 % | 1 | 44.210.496 $ | +44.210.496 $ | 1 | |
| Oric Pharmaceuticals, Inc. | ORIC | → 0 | Schwach | 72.865.496 $ | -12.379.734 $ | -14,5 % | 1 | 85.245.230 $ | +30.209.241 $ | +54,9 % | 1 | 55.035.989 $ | -25.701.403 $ | -31,8 % | 1 |
| Eton Pharmaceuticals, Inc. | ETON | → 0 | Neutral | 78.624.156 $ | +25.020.726 $ | +46,7 % | 1 | 53.603.430 $ | +19.266.931 $ | +56,1 % | 1 | 34.336.499 $ | -9.787.222 $ | -22,2 % | 1 |
| CRISPR Therapeutics AG | CRSP | → 0 | Neutral | 75.771.113 $ | +9.683.254 $ | +14,7 % | 1 | 66.087.859 $ | -6.765.774 $ | -9,3 % | 1 | 72.853.633 $ | -17.185.345 $ | -19,1 % | 1 |
| MBX Biosciences, Inc. | MBX | → 0 | Neutral | 21.445.200 $ | -1.748.250 $ | -7,5 % | 1 | 23.193.450 $ | -43.785.020 $ | -65,4 % | 1 | 66.978.470 $ | +29.815.400 $ | +80,2 % | 1 |
| First Tracks Biotherapeutics, Inc. | TRAX | → 0 | Neutral | 63.871.322 $ | +63.871.322 $ | 1 | |||||||||
| Immunome Inc. | IMNM | → 0 | Schwach | 61.338.073 $ | +13.568.123 $ | +28,4 % | 1 | ||||||||
| Lakefront Biotherapeutics NV | LKFT | → 0 | Neutral | 49.980.228 $ | -33.342 $ | -0,1 % | 1 | 50.013.570 $ | -4.501.221 $ | -8,3 % | 1 | 54.514.791 $ | -3.234.211 $ | -5,6 % | 1 |
| Xencor Inc | XNCR | → 0 | Neutral | 26.326.980 $ | -24.480.970 $ | -48,2 % | 1 | 50.807.950 $ | -21.270.167 $ | -29,5 % | 1 | ||||
| Neurogene Inc. | NGNE | → 0 | Neutral | 39.983.706 $ | +14.353.451 $ | +56,0 % | 1 | 25.630.255 $ | -559.390 $ | -2,1 % | 1 | 26.189.645 $ | +4.157.288 $ | +18,9 % | 1 |
| BridgeBio Oncology Therapeutics, Inc. | BBOT | → 0 | Schwach | 21.512.220 $ | -3.754.758 $ | -14,9 % | 1 | 25.266.978 $ | -10.078.560 $ | -28,5 % | 1 | 35.345.538 $ | +2.653.739 $ | +8,1 % | 1 |
| Zenas BioPharma, Inc. | ZBIO | → 0 | Neutral | 20.037.510 $ | +4.602.785 $ | +29,8 % | 1 | 15.434.725 $ | -13.232.020 $ | -46,2 % | 1 | 28.666.745 $ | +28.666.745 $ | 1 | |
| Stoke Therapeutics, Inc. | STOK | → 0 | Neutral | 24.049.200 $ | +20.793.200 $ | +638,6 % | 1 | 3.256.000 $ | +3.256.000 $ | 1 | |||||
| Fulcrum Therapeutics, Inc. | FULC | → 0 | Schwach | 23.972.510 $ | +23.972.510 $ | 1 | |||||||||
| Structure Therapeutics Inc. | GPCR | → 0 | Schwach | 23.256.129 $ | +23.256.129 $ | 1 | |||||||||
| Legend Biotech Corp | LEGN | → 0 | Neutral | 23.104.000 $ | +23.104.000 $ | 1 | |||||||||
| Vaxcyte, Inc. | PCVX | → 0 | Schwach | 20.763.000 $ | +20.763.000 $ | 1 | |||||||||
| Relay Therapeutics, Inc. | RLAY | → 0 | Neutral | 13.058.607 $ | -5.893.775 $ | -31,1 % | 1 | 18.952.382 $ | +18.952.382 $ | 1 | |||||
| Atara Biotherapeutics, Inc. | ATRA | → 0 | Neutral | 17.816.960 $ | +17.345.885 $ | +3.682,2 % | 1 | 471.075 $ | -9.897.805 $ | -95,5 % | 1 | 10.368.880 $ | +2.155.168 $ | +26,2 % | 1 |
| Aquestive Therapeutics, Inc. | AQST | → 0 | Neutral | 16.957.500 $ | +2.283.750 $ | +15,6 % | 1 | ||||||||
| Voyager Therapeutics, Inc. | VYGR | → 0 | Schwach | 15.731.189 $ | +12.600.874 $ | +402,5 % | 1 | ||||||||
| Erasca, Inc. | ERAS | → 0 | Neutral | 6.045.600 $ | -8.516.400 $ | -58,5 % | 1 | 14.562.000 $ | +14.562.000 $ | 1 | |||||
| Aura Biosciences, Inc. | AURA | → 0 | Neutral | 11.833.336 $ | +11.833.336 $ | 1 | |||||||||
| Odyssey Therapeutics, Inc. | ODTX | → 0 | Neutral | 10.394.434 $ | +10.394.434 $ | 1 | |||||||||
| Eikon Therapeutics, Inc. | EIKN | → 0 | Neutral | 9.560.508 $ | +1.809.537 $ | +23,3 % | 1 | 7.750.971 $ | +7.750.971 $ | 1 | |||||
| MANNKIND CORP | MNKD | → 0 | Neutral | 9.412.200 $ | +9.412.200 $ | 1 | |||||||||
| Nuvation Bio Inc. | NUVB | → 0 | Schwach | 8.631.464 $ | +5.067.132 $ | +142,2 % | 1 | ||||||||
| Pharvaris N.V. | PHVS | → 0 | Neutral | 8.126.300 $ | +8.126.300 $ | 1 | |||||||||
| Replimune Group, Inc. | REPL | → 0 | Neutral | 7.650.000 $ | +7.650.000 $ | 1 | |||||||||
| Zura Bio Ltd | ZURA | → 0 | Neutral | 6.960.319 $ | -58.985 $ | -0,8 % | 1 | 7.019.304 $ | +7.019.304 $ | 1 | |||||
| Phathom Pharmaceuticals, Inc. | PHAT | → 0 | Neutral | 6.781.250 $ | -162.500 $ | -2,3 % | 1 | 6.943.750 $ | +6.943.750 $ | 1 | |||||
| Nurix Therapeutics, Inc. | NRIX | → 0 | Neutral | 6.550.200 $ | +6.550.200 $ | 1 | |||||||||
| Eloxx Pharmaceuticals, Inc. | ELOX | → 0 | Neutral | 5.552.000 $ | +5.552.000 $ | 1 | |||||||||
| Evolus, Inc. | EOLS | → 0 | Neutral | 4.488.750 $ | +4.488.750 $ | 1 | |||||||||
| Mereo BioPharma Group plc | MREO | → 0 | Neutral | 317.700 $ | -4.094.022 $ | -92,8 % | 1 | 4.411.722 $ | +1.137.933 $ | +34,8 % | 1 | 3.273.789 $ | +3.273.789 $ | 1 | |
| iBio, Inc. | IBIO | → 0 | Neutral | 3.007.700 $ | -1.292.340 $ | -30,1 % | 1 | 4.300.040 $ | +4.300.040 $ | 1 | |||||
| Prelude Therapeutics Inc | PRLD | → 0 | Neutral | 3.238.908 $ | +3.238.908 $ | 1 | |||||||||
| Aardvark Therapeutics, Inc. | AARD | → 0 | Neutral | 2.366.749 $ | +2.366.749 $ | 1 | |||||||||
| Helix Acquisition Corp. III | HLXC | → 0 | 2.128.000 $ | +96.000 $ | +4,7 % | 1 | 2.032.000 $ | +2.032.000 $ | 1 | ||||||
| Camp4 Therapeutics Corp | CAMP | → 0 | Neutral | 1.992.250 $ | +1.992.250 $ | 1 | |||||||||
| Surrozen, Inc. | → 0 | 115.322 $ | -14.132 $ | -10,9 % | 1 | 129.454 $ | +29.020 $ | +28,9 % | 1 | 100.434 $ | -758.878 $ | -88,3 % | 1 | ||
| Gesamt | 2.056.733.459 $ | +473.627.665 $ | +202,9 % | 31 | 2.356.318.840 $ | +314.880.802 $ | +7,1 % | 29 | 2.204.008.593 $ | +638.709.769 $ | +61,2 % | 28 | |||